The Fly | QUCY

High-Accuracy Non-Invasive Screening Technology: Mainz Biomed's ColoAlert utilizes a proprietary qPCR-based multi-target approach, aiming for superior sensitivity and specificity in colorectal cancer detection, a key differentiator in the diagnostics market.

Vast Untapped Market Potential: Targeting the significant and growing global colorectal cancer screening market, ColoAlert offers a patient-friendly alternative that can increase screening compliance among the large unscreened population.

Advanced Clinical Development Stage: The ColoFuture pivotal study in the U.S. positions ColoAlert on an accelerated path toward potential FDA approval, significantly de-risking the product for commercialization.

Regulatory Approval Uncertainty: Mainz Biomed's lead product, ColoAlert, requires further regulatory approvals (e.g., FDA) for broader market access, and there is no guarantee these will be obtained in a timely manner or at all, which could significantly delay or prevent commercialization.

Commercialization and Market Adoption Challenges: Even if approved, there is no assurance that ColoAlert will achieve significant market acceptance or compete effectively against established screening methods and other emerging technologies, impacting revenue generation.

Significant Funding Requirements: The company operates at a net loss and will require substantial additional financing to fund ongoing clinical trials, regulatory processes, commercial launch, and operations, which may not be available on favorable terms or at all, leading to potential dilution or cessation of operations.